Trials / Completed
CompletedNCT03974425
One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- University of Alexandria · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Purpose: The aim of this study is to evaluate the functional and anatomical effects of switching from Bevacizumab to Aflibercept in patients with persistent DME resistant to Bevacizumab. Methods: Patients with DME refractory to Bevacizumab (1.25 mg/ 0.05 mL) were subsequently switched to Aflibercept (2.0 mg/0.05 ml). The included patients received 5 loading doses of intravitreal Aflibercept (2.0 mg/0.05 mL) (Eylea; Bayer, Berlin, Germany) given monthly. After the loading dose, Aflibercept was injected every 2 months. The follow up duration was one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept Injection [Eylea] | intravitreal injection of Aflibercept in resistant DME. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-04-01
- Completion
- 2018-04-01
- First posted
- 2019-06-04
- Last updated
- 2019-06-04
Source: ClinicalTrials.gov record NCT03974425. Inclusion in this directory is not an endorsement.